Results of drug price scenario when the interventions refer to an incremental cost-effectiveness ratio of €55 850 per QALY gained relative to dacarbazine
| Interventions | Drug price at which treatment is cost-effective (WTP = €55 850) | Drug cost per month in model | Required rebate for cost-effectiveness at WTP = €55 850 (%) |
| Dabrafenib | 1899 | 9040 | 79 |
| Trametinib | 1675 | 9939 | 83 |
| Dabrafenib+trametinib | 3127 | 18 982 | 84 |
| Vemurafenib | 1787 | 9331 | 81 |
| Vemurafenib+cobimetinib | 3127 | 19 270 | 84 |
| Ipilimumab* | 20 328 | 82 750 | 75 |
| Ipilimumab†+Dacarbazine | 15 190 | 82 750 | 82 |
| Nivolumab | 3574 | 9656 | 63 |
| Nivolumab +Ipilimumab‡ | 33 508 | 138 473 | 76 |
| Pembrolizumab | 3686 | 10 377 | 64 |
*The ipilimumab cost is not per month, but the full treatment drug cost.
†Reduction applies to ipilimumab only.
‡The price reduction was estimated from the total cumulative drugs cost per patient, which combines the cost of ipilimumab and nivolumab.
WTP, willingness-to-pay.